Year: 2020

NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) — GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care, today announced the pricing of its initial public offering of 1,270,589 units at a public offering price of $17.00 per unit. Each unit will immediately separate into (a) one share of the Company’s common stock (or, at the purchaser’s election, one share of Series B Convertible Preferred Stock), (b) one Series A warrant (the “Series A Warrants”) to purchase one share of the Company’s common stock at an exercise price equal to $8.50 per share exercisable until the 5th anniversary of the issuance date, and (c) one Series B warrant to purchase one share of the Company’s common stock at an exercise...

MCLEAN, Va., Dec. 23, 2020 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) has extended to March 31, 2021 the deadline for requesting a new or supplemental COVID-19 forbearance agreement for its Multifamily loans. The program was previously set to terminate at the end of 2020. The extension provides additional time for multifamily operators experiencing continued hardship as a result of the pandemic to request a new or supplemental forbearance agreement, which includes renter protections such as a moratorium on evictions for non-payment of rent.“We are still in the midst of the pandemic, and to continue to provide support for the multifamily market, we are providing additional time for borrowers to request a new or supplemental forbearance agreement,” said Debby Jenkins, head of Multifamily at Freddie Mac. “Our forbearance program...

Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020Combined company renamed Vincera Pharma, Inc., common stock commences trading tomorrow, December 24, 2020 on the Nasdaq Capital Market under ticker symbol “VINC”Net Proceeds from this transaction are approximately $62 millionCompany to host business update conference call and webcast on Tuesday, January 5, 2021 at 8:30 AM Eastern TimeSANTA CLARA, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — Vincera Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the completion of its business combination with LifeSci Acquisition Corp. (Nasdaq: LSAC; LSACU; LSACW; or “LSAC”), a blank check company targeting the biopharma, medical...

Financial calendar for Seabird Exploration PLCFINANCIAL YEAR 202029.01.2021 – Quarterly Report – Q4FINANCIAL YEAR 202130.07.2021 – Half-yearly Report30.04.2021 – Annual Report25.05.2021 – Annual General Meeting30.04.2021 – Quarterly Report – Q122.10.2021 – Quarterly Report – Q328.01.2022 – Quarterly Report – Q4This information is published pursuant to the requirements set out in the Continuing obligations.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.Oslo, 23 December 2020: Reference is made to the stock exchange announcement on 21 July 2020 and subsequent announcements relating to Adevinta ASA’s (the “Company”) agreement to acquire eBay Classifieds (the “Target”) from eBay Inc. (“eBay”) (the “Transaction”).Subject to the terms and conditions of the Transaction, the Company shall acquire the Target against consideration in the form of cash and a total of 539,994,479 new shares in the Company (the “Consideration Shares”). The Consideration Shares will comprise...

Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020$33.6 million common stock private investment in public equity (“PIPE”) transaction closes concurrently with the mergerBOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) — Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that its reverse merger with Proteostasis Therapeutics, Inc. closed on December 22, 2020, following the approval of Proteostasis shareholders. The combined company will operate under the name Yumanity Therapeutics, Inc., and its shares will commence trading on the Nasdaq Capital Market on December 23, 2020, under the ticker symbol “YMTX.” The $33.6 million PIPE transaction,...

Information about mandatory offer of share repurchaseJoint Stock Company “Grindeks” hereby informs that today according to 22nd December, 2020 Financial Capital Market Commission decision and the official announcement of the publisher “Latvijas Vestnesis” of December 23 rd, 2020, JSC “Grindeks” shareholder “Liplat Holding” Ltd. will begin the mandatory share repurchase offer process.The following details of this mandatory share repurchase offer (the “Offer”) are being published in accordance with section 73(4) of the Financial Instruments Market LAWAct (“FIML”):The TargetThe Target Company of the Mandatory Share Repurchase Offer: JSC “Grindeks”,  registration number 40003034935; legal address: Riga, Krustpils Street 53, postal code: LV-1057, Latvia, T: +371 67083500, e-mail: grindeks@grindeks.lv, website: www.grindeks.lv.Offeror“Liplat...

Par obligāto akciju atpirkšanas piedāvājumuAkciju sabiedrība „Grindeks” informē, ka šodien, ievērojot Finanšu un kapitāla tirgus komisijas padomes 2020. gada 22. decembra lēmumu un atsaucoties uz 2020. gada 23. decembra paziņojumu oficiālajā izdevējā „Latvijas Vēstnesis”, sāksies AS „Grindeks” akcionāra SIA „Liplat Holding” izteiktais obligātais akciju atpirkšanas piedāvājums.Saskaņā ar Finanšu instrumentu tirgus likuma 73. panta ceturto daļu par obligāto akciju atpirkšanas piedāvājumu tiek publicēta šāda informācija:Informācija par piedāvājumuMērķa sabiedrība: AS „Grindeks”, vienotais reģistrācijas numurs 40003034935; juridiskā adrese: Rīga, Krustpils iela 53, LV-1057, Latvija, tālr.: +371 67083500, e-pasts: grindeks@grindeks.lv, interneta mājaslapa: www.grindeks.lv.PiedāvātājsSIA „Liplat Holding”, reģistrēta 11.04.2019 ar reģistrācijas...